Bicycle Therapeutics PLC (BCYC)
21.79
-0.79
(-3.50%)
USD |
NASDAQ |
Nov 15, 16:00
21.76
-0.02
(-0.11%)
After-Hours: 20:00
Bicycle Therapeutics Research and Development Expense (TTM): 167.88M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 167.88M |
| June 30, 2024 | 159.49M |
| March 31, 2024 | 159.15M |
| December 31, 2023 | 156.50M |
| September 30, 2023 | 136.52M |
| June 30, 2023 | 119.40M |
| March 31, 2023 | 99.54M |
| December 31, 2022 | 81.61M |
| September 30, 2022 | 69.85M |
| June 30, 2022 | 57.61M |
| March 31, 2022 | 49.48M |
| December 31, 2021 | 44.88M |
| Date | Value |
|---|---|
| September 30, 2021 | 41.99M |
| June 30, 2021 | 38.84M |
| March 31, 2021 | 35.07M |
| December 31, 2020 | 33.15M |
| September 30, 2020 | 29.74M |
| June 30, 2020 | 28.46M |
| March 31, 2020 | 27.04M |
| December 31, 2019 | 25.54M |
| September 30, 2019 | 25.38M |
| June 30, 2019 | 24.95M |
| March 31, 2019 | 23.33M |
| December 31, 2018 | 20.76M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
25.54M
Minimum
Dec 2019
167.88M
Maximum
Sep 2024
78.09M
Average
53.54M
Median
Research and Development Expense (TTM) Benchmarks
| Adaptimmune Therapeutics PLC | 143.17M |
| NuCana PLC | 35.08M |
| TC BioPharm (Holdings) PLC | -- |
| Autolus Therapeutics PLC | 129.68M |
| Biodexa Pharmaceuticals PLC | -- |